Many mAbs including pembrolizumab and durvalumab, which were FDA approved for many other cancers, are currently under investigation for HER2+ BC particularly to evaluate dose-limiting toxicities, maximum tolerated dose (MTD), recommended phase-II dose (RP2D), and objective response (OR). This evidence concerns the gene ERBB2 and breast cancer.